A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Inclusion Criteria: * Body mass index (BMI) ≥ 30 kg/m\^2 * Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) ≥ 10% as evaluated by central review * FibroScan-based transient elastography ≥ 9.9 kPa * Alanine aminotransferase (ALT): \> 30 U/L * If available, historical diagnosis of non-alcoholic steatohepatitis (NASH) according to NASH Clinical Research Network classification by liver biopsy within 6 months before screening will be recorded * Must agree to follow specific methods of contraception, if applicable Exclusion Criteria: * Women who are breastfeeding * Inability to tolerate the mixed meal or the testing conditions, oral medication, venipuncture and/or inadequate venous access * History or current diagnosis of cirrhosis, hepatocellular carcinoma (HCC), or hepatic decompensation * Recent history (within 2 years before screening) of drug or alcohol abuse or excessive alcohol intake, defined as 30 g/day (men) or 20 g/day (women) * Use of lipase inhibitors such as orlistat within 4 weeks before screening or during screening * Use of glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks before screening or during screening * Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg) during screening, unless discussed with the Medical Monitor * Glycated hemoglobin (HbA1c) ≥ 9.5% * NASH-modifying therapies including investigational therapies (e.g., obeticholic acid, ursodeoxycholic acid) within 90 days before screening or during screening * Medications for obesity within 12 weeks before screening, or during screening * If taking vitamin E at a dose ≥ 800 mg/day, the dose must be stable beginning at least 6 months before screening and should remain stable during screening * If taking a thiazolidinedione, the dose must be stable beginning at least 12 weeks before screening and should remain stable during screening * If taking a dipeptidyl peptidase (DPP)-4 inhibitor or other medications for diabetes, the dose must be stable beginning at least 12 weeks before screening and should remain stable during screening * If taking insulin, the dose may be altered by up to 10% within 12 weeks before screening and during the screening period * If taking a statin or other prescription or over-the-counter lipid-lowering drug, the dose must be stable beginning at least 6 weeks before screening and should remain stable during screening Other protocol-defined inclusion/exclusion criteria apply